China Resources Boya Bio-pharmaceutical (SZ:300294) Sou Hu Cai Jing·2026-01-05 15:10Core Viewpoint - Boya Bio (300294) has announced its participation in the establishment of the second phase of the China Resources Pharmaceutical Industry Investment Fund, contributing 60 million RMB to a total fund size of 1 billion RMB [1] Group 1: Stock Performance - As of January 5, 2026, Boya Bio's stock closed at 22.97 RMB, up 1.64% from the previous trading day [1] - The stock opened at 22.59 RMB, reached a high of 23.01 RMB, and a low of 22.59 RMB, with a trading volume of 97.67 million RMB and a turnover rate of 0.85% [1] Group 2: Fund Establishment - The board of directors and supervisory board of China Resources Boya Bio Pharmaceutical Group approved the investment in the second phase of the fund on July 17, 2025 [1] - The fund has been registered with the Asset Management Association of China, with a registration code of SBLL28, managed by Shenzhen China Resources Capital Equity Investment Co., Ltd., and custodied by China Merchants Bank [1] - The registration was completed on December 30, 2025, and the first phase of capital contribution has been fulfilled [1]